Transplantation and Immunosuppressive Drugs Flashcards

1
Q

Define transplantation.

A

Transplantation can be defined as the introduction of biological material (e.g. organs, tissue, cells) into an organism.

The problem with that is that the immune system has evolved to remove anything it regards as non-self.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

List the different types of donor/recipient relationships.

A
  • autologous
  • syngeneic
  • allogeneic
  • xenogeneic
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Describe autologous donor/recipient relationships.

A

Autologous transplantation is the transplantation of tissue from one part of an organism into another part of the same organism.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Describe syngeneic donor/recipient relationships.

A

Syngeneic transplantation is when a donor donates part of their tissue to a recipient, but they are genetically identical.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Describe allogeneic donor/recipient relationships.

A

Allogenic transplantation is when a donor donates part of their tissue to a recipient, but they are genetically different.

An example of this would be siblings, or relatives.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Describe xenogeneic donor/recipient relationships.

A

This is the transfer of tissue from an organism of one species to another.

This is not common; there have only been a few cases where this happens with success.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Describe the importance of MHCs in transplants.

A

MHCS are major histocompatibility antigens.
The human MHC is called HLA, Human Leukocyte antigen. It defines tissue compatibility.

Immune responses to transplant are caused by genetic differences between the donor and the recipient.

The most important are differences between the antigens forming the major histocompatibility complex (MHC).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Describe HLA diversity (where it is found in the genome).

A

The HLA gene is found on chromosome 6.

The alleles are split up into Class I (consisting of 3 alleles) and II (consisting of 6 alleles). The Class II molecules are heterodimers, while Class I are monomers.

Almost all nucleated cells present HLA Class I, while immune cells present both Class I and Class II.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is the importance of epitopes on donor MHC?

A

At the current time, HLA are typed, and the donor and recipient are matched based on typing information. There are many ways of doing it, sequencing being the best one. The trouble is that there are 1000s of HLA.

NGS can be used to identify the epitopes on the HLA, rather than the HLA themselves. There could be two HLAs that have genetic differences, but don’t have any different epitopes. It’s possible that the actual number of epitopes that are important in rejection is far fewer than the HL alleles. In terms of matching, we are moving from matching HLA to matching alleles on HLA.

This could be much better, but NGS is more expensive so cannot be done routinely.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Describe how APCs activate different T-cells.

A

Antigen-presenting cells will express MHC Class I and MHC Class II; this is where the variation is in the molecule.

The TCR detects a combination of both the peptide and the MHC, so it is a peptide-MHC or peptide-HLA complex that the TCR is detecting.

MHC Class I will activate TCR in CD8 T Cells, and MHC Class II will activate TCR in CD4 T Cells.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Describe MHC II loading in cells.

A

This is only on professional APCs.
These cells are good at taking up external material, which they will process in the phagolysosome into peptides. These peptides interact with the vesicle containing MHC and CLIP (maintains the shape of HLA until the peptides arrive).

When the peptides bind, the complex goes to the cell surface to activate CD4 T cells.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is the key point about the differences in which cells have which class of MHC?

A

All cells have the MHC Class I, which means that if they are infected by a virus or bacteria, they can alert the immune system of it so that they are targeted or removed by CD8 cytotoxic cells.

MHC Class II is only on immune cells, so that when those cells have got to the site of infection and internalised the infectious material, they can present them to CD4 T cells to orchestrate a more robust and long-lasting immune response. Thus, they need more regulation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

As a recap, what is the difference between helper T cells and cytotoxic T cells?

A

Helper T cells – information and support for other immune cells via cytokine production

(helper T cells are required to produce antibody and cytotoxic T cell response)

Cytotoxic T cells – highly specific killer cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What are the two ways in which foreign bodies can be recognised?

A

There can be direct recognition of the HLA, or indirect recognition of the peptide as foreign.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Describe indirect and direct recognition.

A

If the patient has had a transplantation, the HLA can present a non-self antigen, and you get indirect allo-recognition.

When you have an unmatched donor HLA, you will get direct allo-recognition because the TCR of the recipient T cells will detect this MHC.
You may also have a donor peptide in there, but even if the peptide itself isn’t recognised as foreign, the fact that the HLA is unmatched means that the combination of peptide-HLA is different, and TCR will get activated.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Why is is so important to match HLA?

A

HLA mismatch correlated to the graft survival.

Even with no mismatches, the 10-year estimate of survival is only 33%.
This isn’t even with taking into account the immunosuppressive medicine, and the complications arising from that.

17
Q

What is the drawback with dead donors?

A

There could be more inflammation from deceased donor tissue. The recipient who needs the transplant will also have a degree of chronic inflammation, and the donor inflammation can exacerbate the immune response to mismatches.

Thus, success is better when you use live donors.

18
Q

What are the three types of graft rejection?

A
  • hyper-acute rejection
  • acute rejection
  • chronic rejection
19
Q

Describe hyper-acute rejection.

A

It occurs within a few hours of the transplant.
It’s commonly seen is highly-vascularised organs (such as the kidney) because the immune response can easily access highly-vascularised tissue.

It requires pre-existing antibodies, usually to ABO blood group antigens or MHC-I proteins (ABO antigens are expressed on endothelial cells of blood vessels).

Antibodies to MHC can arise from pregnancy, blood transfusion or previous transplants.

20
Q

How can antibodies cause damage to transplanted tissue?

A

This works by the pre-existing antibodies detecting the antigen on the donor tissue.
The Fc region (which is normally conserved) on the antibody binds to the antigen. This can also bind to Fc receptors on immune cells.

This is an innate immune response using adaptive antibody binding.

The binding of the Fc region allows for complement activation.
This could be antibody-dependent cellular cytotoxicity, where cells such as NK cells kill the cell bound to the antibody.
It could also be phagocytosis, by cells such as macrophages.

The reason this happens so quickly is due to the pre-existing antibodies and the complement fixation.

Whilst it kills individual cells, it also causes a build-up of inflammatory cells in endothelium, which results in damage to the endothelial cells, so the tissue is not sufficiently vascularised, and the tissue can die.

21
Q

Describe acute rejection.

A

In acute rejection, we have an example of direct allo-recognition. The dendritic cells in the donor transplant can migrate from the organ to the lymph nodes, where they encounter recipient T cells.

They interact with the T cells, and since there is an MHC mismatch, the TCR receptors on the T cells are activated.

The donor dendritic cells will have MHC Class I and II, as they are professional immune cells, so they will activate both CD8 and CD4 T cells.

Those T cells will proliferate and migrate to the donor organ, and target the cells in the tissue and destroy the transplant.

22
Q

Describe chronic rejection.

A

This is an example of indirect allo-recognition, so it is to do with the peptide sitting in the complex. The MHC mismatch effect is less pronounced and occur months or years after the transplant.

It correlates with the presence of antibodies to MHC Class I.

The blood vessel walls are thickened, and the lumina is narrowed - this leads to a loss of blood supply.

Thus, in the transplant, donor cells will die. Those cells are taken up by recipient APCs. They break down the cells, and present the non-self HLA as peptides, which activate T cells and lymph nodes.
They are now reactive to the foreign peptide, and will target the donor cells and kill them.

23
Q

Describe HSCT.

A

HSCT is Haematopoietic Stem Cell Transfer.

Here, the recipient’s immune response is removed and the stem cells transfer from a donor provides a new immune system.

Sometimes, this is using stem cells from the same patient; in this case, there won’t be an immune response.

More recently, stem cell (or bone marrow) transplant from a donor to a recipient occurs. However, this can induce graft-vs-host disease, where the donor immune system attacks the recipient.

24
Q

Describe GVHD.

A

GVHD is Graft-Versus-Host Disease.

When transplanted tissue is immune cells themselves, there is the risk of donor immune cells attacking the host - resulting in GVHD.

It can be lethal - it’s best to stop it at the early activation stage, when it isn’t too prevalent.

One way to do that is to remove the T cells or suppress their function, except then you don’t have an immune response.

25
Q

When can GVHD be advantageous?

A

There is one scenario where GVHD can be advantageous.

We can use the stem cell transfer to remove any remnants of original leukaemia in a patient.

The donor immune system will be able to target the cancer in a way that the host immune system can’t.

The problem with our immune response against cancer is that the cancer derives from self, so our immune system struggles to identify it. If we have a donor immune system, it doesn’t have that problem, due to the HLA mismatch.

26
Q

What is the importance of immunosuppression?

A

It’s essential to maintain non-autologous transplants.

There are various phases:

  • INDUCTION: to try and prevent the build-up of an immune response
  • MAINTENANCE: may require changing medication or lower doses depending on the side effects experienced
  • RESCUE: if the immune response starts to mount towards the transplant, you have a rescue phase

Immunosuppressives may need to be maintained indefinitely.

27
Q

List some examples of immunosuppressants.

A

General immune inhibitors (e.g. corticosteroids)

Cytotoxic – kill proliferating lymphocytes (e.g. mycophenolic acid, cyclophosphamide, methotrexate)

Inhibit T-cell activation (cyclosporin, tacrolimus, rapamycin)

28
Q

Describe cyclosporin.

A

It was a breakthrough drug for transplants.

It blocks T cell proliferation and differentiation. Even if there was a nascent immune response against the transplant, it cannot develop into an effective cytotoxic response.

Now, next generation therapies less toxic and effective at lower doses.

29
Q

List some examples of next generation therapies in immunosuppression and their mechanism of action.

A
  • Cyclosporin and FK506 (Tacrolimus): inhibits production of IL-2 (IL-2 stimulates proliferation in T-cells).
  • Mycophenolic acid: blocks lymphocyte proliferation through inhibition of DNA synthesis in T and B cells
  • Rapamycin: blocks lymphocyte proliferation by inhibiting IL-2 signalling
  • Steroids: they stop general anti-inflammatory effects from taking hold
  • Anti-CD3 monoclonal antibody: depletes T cells by targeting them for destruction
  • Anti-IL-2 receptor antibody: inhibits T cell proliferation by blocking IL-2 binding; it may also promote phagocytosis and complement activation
30
Q

Why are combination therapies preferred over single-drug therapies?

A

Combinations are normally more effective than taking a single drug.

It will also allow you to lower the dose of both of them, and reduce the side-effects.

31
Q

Why is immunosuppressive therapy monitoring important?

A

There is currently no immunosuppressive that will prevent transplant rejection whilst maintaining other immune responses.
Thus, the patient needs to be monitored to ensure that their immune response isn’t too suppressed, as they are more susceptible to infection and cancer.

Immunosuppressive drug toxicity can also lead to organ failure.

32
Q

What is the role of the intestinal microbiome in transplants?

A

The microbiome, particularly of the intestine, is involved in regulating adaptive immune responses.

Immunosuppressed patients (e.g. cancer patients) can take FMT – faecal material transplant – in order to promote effective anti-cancer immune responses.

Thus, it may be implicated in transplantation outcomes.